

Drug Monograph

Drug / Drug Class: **Dymista™ (azelastine hydrochloride and fluticasone propionate) spray/ H1-receptor antagonist and corticosteroid agent**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Dymista™ Nasal Spray contains 137 mcg of azelastine hydrochloride and 50 mcg of fluticasone propionate in each 0.137 mL spray actuations. Each bottle of Dymista™ Nasal Spray contains 120 actuations.

Manufacturer: For: Medco Pharmaceuticals, Sommerst, NJ 08873
By: Cipla Ltd. Goa, India

Indications: Dymista™ Nasal Spray is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 12 years of age and older who require treatment with both an H1-receptor antagonist and corticosteroid for symptomatic relief.

Costs: \$ 138.99 per bottle of Dymista™ Nasal Spray. Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications PA Required

Prepared By: Katie Wilbers, PharmD

Date: August 16, 2012